Practice Areas:

Ms. Wang's practice focuses on life sciences and healthcare, mergers, acquisitions and corporate restructuring, cross-border investment, and corporate compliance.

Ms. Wang has extensive experience in corporate and transactional matters. She has represented numerous Fortune Global 500 companies, USD funds, RMB funds, large state-owned groups, and privately held enterprises in a wide range of transactions, including control acquisitions, equity investments from angel rounds through pre-IPO rounds, establishment of and exit from joint ventures, asset sales and licensing transactions, and offshore listings. She is known for delivering commercially valuable legal solutions with sharp business acumen and outstanding communication skills.

Ms. Wang has deep experience in the healthcare industry. She has provided comprehensive legal services to multinational pharmaceutical groups, domestic innovative drug companies, and medical device companies on matters including R&D, clinical trials, product launch, commercialization, MAH transfers, licensing in/out, ODM/OEM manufacturing, compliance system development, and overseas expansion.

Ms. Wang's major clients have included Ant Health, Bristol Myers Squibb, Fresenius, Johnson & Johnson, Pfizer, Novartis, Philips, CapitaLand, Sinopharm, Connect Biopharma, CStone Pharmaceuticals, Inmagene, WuXi AppTec, NIO, Alibaba Health, XtalPi, Innovusion (Seyond), Ustar Biotechnologies, Goldman Sachs, The Carlyle Group, Temasek, Centurium Capital, CICC Capital, Hillhouse Capital, CBC Group and CPE, among others.

Education:

Ms. Wang received her Bachelor of Science degree from the College of Pharmaceutical Sciences, Zhejiang University, and her Juris Master (Chinese law) and Juris Doctor (U.S. law) degrees from Peking University School of Transnational Law. She is also a member of LawWithoutWalls.

Professional Experience:

Ms. Wang joined T&C Law Firm in 2024. Prior to that, she practiced for many years at Fangda Partners and JunHe LLP, and also served as in-house counsel at Fosun Group and Bristol Myers Squibb.

Selected Publications:

Overview of the Key Amendments to the GCP, June 2026

Bridging Past and Future: Commentary on the Key Amendments to the Implementing Regulations of the Drug Administration Law, February 14, 2026

An Overview of the Current State of AI Healthcare Regulation, December 15, 2025

The Scope and Implications of the Compliance Guidelines on Anti-Commercial Bribery Risks, March 1, 2025

White Paper on Chinese Medical Devices Entering Southeast Asia, October 2024

Swift Waters Ahead: A Brief Commentary on the Medical Device Administration Law (Draft for Comment), September 2024

Gathering Storm: A Close Look at the U.S. BIOSECURE Act, June 2024

Interpretation of the New Regulations on Contract Manufacturing of Medical Devices, May 2024